The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Reviewing the Clinical LandscapeFull Access

Illegal or Legal, Marijuana Remains a Gateway Drug

Published Online:https://doi.org/10.1176/appi.focus.164S01

Because I continue to be concerned about the impact of marijuana legalization, two articles related to this topic caught my eye. In the first article, Hasin and colleagues (1) investigated whether increases in adult illicit cannabis use and cannabis use disorders followed implementation of medical marijuana laws. The authors used three national cross-sectional adult surveys, one from 1991–1992, one from 2001–2002, and one from 2012–2013. Over the entire 20-year period, the predicted prevalence of illicit use and disorders increased to a greater degree in the states that passed medical marijuana laws than in other states. Medical marijuana laws seem to have contributed to increasing adult use and cannabis disorders.

In the second article, Olfson and colleagues (2) examined the speculation that cannabis might help to curb or prevent opioid use disorders, which arose from reports that annual death rates caused by opioid overdoses were significantly lower in states that permit medical marijuana. Olfson and colleagues (2) used data from the National Epidemiological Survey on Alcohol and Related Conditions (wave 1 in 2001–2002 and wave 2 follow-up in 2004–2005). They found that cannabis use was strongly associated with subsequent onset of nonmedical prescription opioid use and opioid use disorder (nonmedical prescription use was defined as using analgesics “without a prescription, in greater amounts, more often, or longer than prescribed, or for a reason other than a doctor said you should use them”). Thus, cannabis seems to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorders.

Legalization of marijuana leads to an increase in cannabis use and risk of cannabis use disorders, and cannabis use is associated with an increase in nonmedical prescription opioid use and opioid use disorders. These findings seem to confirm rather than refute the old observation that marijuana is a gateway drug. They also suggest the fallacy of medical marijuana laws and predict more work for addiction specialists and physicians in general.

Dr. Balon is with the Departments of Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne State University, Detroit.
References

1 Hasin DS, Sarvet AL, Cerdá M, et al.: US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991–1992 to 2012–2013. JAMA Psychiatry 2017; 74:579–588CrossrefGoogle Scholar

2 Olfson M, Wall MM, Liu S-M, et al.: Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 2018; 175:47–53CrossrefGoogle Scholar